Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTRON vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Mild to moderate pain,Fever
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1, SULT1A3), and oxidation (CYP2E1, CYP3A4) to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
>99% bound to albumin.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.1-0.2 L/kg; indicates limited extravascular distribution.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: 70-90% (first-pass metabolism minimal); IV: 100%.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
GFR <30 m L/min: Avoid use. GFR 30-50 m L/min: Reduce dose to 50% of normal, maximum 600 mg/day.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Child-Pugh Class B: Reduce dose by 50%; maximum 600 mg/day. Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Children ≥12 years: 400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Children <12 years: Not recommended.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Initiate at 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases involve use of acetaminophen at doses exceeding 4000 mg per day, often involving more than one acetaminophen-containing product.
There is no FDA black box warning for ALPHACAINE.
Hepatotoxicity: risk increased with chronic alcohol use, liver disease, or use of other acetaminophen-containing products. Avoid exceeding 4000 mg/day. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. Hypersensitivity reactions: anaphylaxis.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Severe hepatic impairment or active liver disease. Known hypersensitivity to acetaminophen or any component of the formulation.
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Avoid alcohol; may increase risk of GI bleeding. No specific food restrictions, but taking with food can reduce gastrointestinal irritation. Maintain adequate hydration to prevent renal impairment.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios with prolonged use. Avoid after 30 weeks gestation.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Excreted in breast milk; M/P ratio 0.15. Low oral bioavailability to infant; considered compatible with breastfeeding. Monitor infant for sedation or feeding problems.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
Dose adjustment not typically required; however, due to increased renal clearance and volume of distribution in pregnancy, higher doses may be needed to achieve therapeutic effect. Use lowest effective dose for shortest duration.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
ACTRON (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) for short-term management of moderate to severe acute pain, typically not exceeding 5 days due to risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with active peptic ulcer disease, bleeding diathesis, or advanced renal disease. Monitor renal function and signs of bleeding. Use lowest effective dose for shortest duration. May cause bronchospasm in aspirin-sensitive asthma.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Take with food or milk to reduce stomach upset.,Do not take for more than 5 days as prescribed; longer use increases risk of serious side effects.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Report any signs of bleeding (e.g., black stools, vomiting blood), unusual bruising, or decreased urination.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting your doctor.,Inform your doctor about all medications, especially blood thinners (e.g., warfarin) and diuretics.,If you have asthma, be aware of potential bronchospasm; seek immediate help if you have breathing trouble.,Not recommended during pregnancy, especially in the third trimester.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTRON vs ALPHACAINE, answered by our medical review team.
ACTRON is a NSAID that works by Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTRON and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTRON is: Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTRON and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTRON is classified as Category C. First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closur. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.